<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525758</url>
  </required_header>
  <id_info>
    <org_study_id>SI000413_OA_Ⅱ</org_study_id>
    <nct_id>NCT01525758</nct_id>
  </id_info>
  <brief_title>Study of SI000413 in Knee Osteoarthritis Patients</brief_title>
  <official_title>Eight-week, Multi-centre, Dose-response, Double Blind, Placebo-controlled, Randomized, Parallel-group, PhaseⅡ Trial to Evaluate Efficacy and Safety of SI000413 in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of SI000413 in patients with
      knee osteoarthritis by orally administration and to determine optimal dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-response, double blind , placebo-controlled study. All patients are required
      to have 2 weeks washout period from prior medication. Subjects will discontinue current
      medications 2 weeks prior to randomization. Among those who meet the inclusion criteria, only
      subjects recording visual analogue scale(VAS) of higher than 40mm(VAS range from 0mm(no pain)
      to 100mm(unbearable pain)) are enrolled in this study.

      Subjects meeting screening criteria will be randomized to receive 8 weeks dosing of an active
      dose of SI000413 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>K-WOMAC</measure>
    <time_frame>Visit 6(8 week), baseline</time_frame>
    <description>The primary endpoint will be the change in the sum of the K-WOMAC OA index at Visit 6(8 weeks) vs. baseline(Visit 2, 0 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>knee pain intensity assessment</measure>
    <time_frame>baseline, Visit 4(4 week), Visit 6(8 week)</time_frame>
    <description>The change from baseline to each day(4 week and 8 week). Subjects assess knee pain intensity by using 100mm VAS at each time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment(regarding to disease activity)</measure>
    <time_frame>Visit 4(4 week), Visit 6(8 week)</time_frame>
    <description>The change from Visit 4 to Visit 6 using 100mm VAS. Each patient and investigator assess by using 100mm VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-WOMAC each domain assessment</measure>
    <time_frame>baseline, Visit 6(8 week)</time_frame>
    <description>The change from Visit 6(8 weeks) vs. baseline(Visit 2, 0 week) in the K-WOMAC each domain score.
* K-WOMAC 3 domains: pain domain, stiffness domain, physical function domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR &amp; hs-CRP</measure>
    <time_frame>baseline, Visit 4(4 week), Visit 6(8 week)</time_frame>
    <description>The change from baseline to each day(Visit 4, Visit 6) using laboratory test.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>SI000413 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, SI000413 200mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI000413 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, SI000413 200mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI000413 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SI000413 200mg, 2T bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 2T tid for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SI000413</intervention_name>
    <description>1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks</description>
    <arm_group_label>SI000413 400mg</arm_group_label>
    <arm_group_label>SI000413 600mg</arm_group_label>
    <arm_group_label>SI000413 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>microcrystalline cellulose</intervention_name>
    <description>identical number of tablets to active drug groups</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>SI000413 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females, 35-75 years old

          2. Subjects must have a clinical or radiographic diagnosis of primary OA of the knee
             (diagnosed according to the ACR)

               -  The presence of knee pain

               -  At least one of the following

                    -  age older than 50 years

                    -  morning stiffness lasting less than 30 minutes

                    -  crepitus with motion

          3. Subjects must have been symptomatic for at least 3 months prior to enrollment.

          4. Subjects must be required to have experienced a pain intensity of at least 40mm on a
             100-mm visual analogue scale in the most severely affected joint during the 24 hours
             prior to randomization.

          5. Adequate liver and kidney function

               -  Adequate liver function : SGOT, SGPT must be within 1.5 x normal limit

               -  Adequate kidney function : Serum creatinine must be within 1.5 x normal limit

          6. Subjects must be able to read, understand and follow the study instructions

          7. Subjects must agree to informed consent spontaneously.

        Exclusion Criteria:

          1. Subjects who are not using adequate birth control.

          2. Pregnant or breast-feeding.

          3. Subjects requiring Knee surgery within 1 year of screening anticipating any need for a
             surgical procedure during the study.

          4. Secondary OA patients

          5. Similar OA patients(ex. rheumatic arthritis, bursitis etc)

          6. Treatment with intra-articular injections of systemic corticosteroids or hyaluronic
             acid in the prior 3 months.

          7. Use of drugs or psychotropic medicine(methadone maintenance program, codeine, tramadol
             hydrochloride)

          8. Anemia or coagulant disorder

          9. Use of anticoagulants or lithium

         10. Use of misoprostol or H2-blocker(including anti ulcer medicine)

         11. Presence or history of gastrointestinal bleeding within the past 1 year.

         12. Subjects who have serious problem with cardiovascular, respiratory, endocrine, central
             nervous or History of neurotic mental.

         13. Active malignancy of any type(ex. lymphoma, multiple myeloma etc)

         14. Use of any medication that will affect pain perception during the study period;
             physical therapy, corticosteroids, NSAIDs, asprin, topical analgesics.

         15. Use of glucosamine, chondroitin during the study period.

         16. Change of concomitant dose/use within 4 weeks.

         17. Known allergy or hypersensitivity to medicine.

         18. Subjects received hormone replacement therapy.

         19. Use of any other investigational drug within 1 month prior to screening.

         20. Investigators determines that it is not appropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Jae Cho, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Chul Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>We-Yeon Won, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoon-Jae Cho, MD</last_name>
    <email>yjcho@khmc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>KyungHee University medical center</name>
      <address>
        <city>Seoul</city>
        <state>Hoegi-dong, Dongdaemun-gu</state>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoon-Jae Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Woncheon-dong Yeongtong-gu, Suwon</state>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>We-Yeon Won, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yongon-dong, Chongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Myung-Chul Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

